PROPRANOLOL IN INFANTILE HEMANGIOMA TREATMENT – EXPERIENCE IN 2 CASES

• Autor(a) principal: Carvalho, Rodrigo
• Data de Publicação: 2011
• Outros Autores: Freitas, Isabel, Henrique, Martinha, Cardoso, Jorge
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://doi.org/10.29021/spdv.69.3.91

Introduction: Infantile hemangioma is the benign tumor more frequent in pediatric age. The majority was a good outcome however, depending on location they can distort important anatomic structures or take to local or systemic complications. In this context, since Léauté-Labréze published in 2008 their experience with propranolol, multiple case reports and small series have been reported in international literature where this drug is used “off-label” as first line therapeutic agent. The present work aims to report the experience of a department with propranol as first line drug in infantile hemangioma treatment in 2 patients. Clinical cases: The patient 1 was a female with infantile hemangioma since 5 weeks old localized at the nose. The patient 2 was a male with two ulcerated infantile hemangiomas: one at the face, and another at the scrotum. Both underwent therapeutic induction with propranol on an inpatient basis, with a target dose of 2-3 mg/Kg/day. After a 6 months follow-up period, a good response was achieved with no complications noted. Discussion: Propranol is a safe and effective alternative in hemangioma treatment. Although no complications were noted, they are described and occur mainly during the therapeutic induction, making important the clinical vigilance during this period.KEYWORDS – Infant, Hemangioma; Propranolol; Skin Neoplasms; Therapy.